TARSUS PHARMACEUTICALS, INC. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↑+128.4% +$85M
$152M
Cost of Revenue
—
R&D↑+6.9% +$1M
$18M
SG&A↑+89.3% +$62M
$131M
D&A↑+5.2% +$10K
$202K
Operating Income↑+42.3% +$11M
$-15M
EBITDA↑+5.2% +$10K
$202K
Interest Expense↓-4.2% -$98K
$2M
Tax Provision
$2M
Net Income↑+46.3% +$11M
$-13M
Operating Margin↑+40.1pts
-12.2%
Net Margin↑+38.1pts
-10.6%
ETR (Continuing Operations)↓-3.2pts
-3.2%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↓-2.5pts
-2.5%
Operating Lease Cost↑+338.4% +$741K
$960K
Revenue YoY Variation↓-279.5pts
128.4%
Income YoY Variation↑+3.7pts
42.3%
Revenue QoQ Variation↓-10.2pts
27.8%
Income QoQ Variation↑+10.1pts
34.5%